Edwards Lifesciences (EW) Tops Q1 EPS by 5c; Issues Solid Outlook
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/14/2026
- Wall St futures muted as oil gains curb risk appetite after S&P record close
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
- Reddit to join S&P 500 index on Aug. 18, shares leap
Edwards Lifesciences Reports First Quarter Results
April 26, 2016 4:15 PM EDTIRVINE, Calif., April 26, 2016 /PRNewswire/ -- Edwards Lifesciences Corporation (NYSE: EW), the global leader in patient-focused innovations for structural heart disease and critical care monitoring, today reported financial results for the quarter ended March 31, 2016.
First Quarter Highlights:
Sales grew 18.1% to $697.3 million, and underlying1 sales were up 19.7% THVT sales grew 37.0%, and underlying sales were up 38.3% GAAP EPS was $0.66, an increase of 17.9%, and adjusted2 EPS grew 24.6% to $0.71 2016 sales guidance raised to $2.7 - $3.0 billion from $2.6 - $2.85... More